Stocks · News reference

Minerva Neurosciences shares are trading higher after Jefferies upgraded the stock from Hold to Buy rating and raised the price target from $7.5 to $10.

Aug 14, 2026, 6:01 PMBenzinga Newsdesk

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaAug 14, 2026, 12:55 PMAvi Kapoor
This Capricor Therapeutics Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday
Wall Street analysts revised their ratings for top stocks. Visit benzinga.com/analyst-stock-ratings for all changes, including upgrades and downgrades.
Read original at benzinga
CAPR CSQR DLR LUNR NERV
BenzingaAug 14, 2026, 12:41 PMBenzinga Newsdesk
Jefferies Upgrades Minerva Neurosciences to Buy, Raises Price Target to $10
Jefferies analyst Biren Amin upgrades Minerva Neurosciences (NASDAQ:NERV) from Hold to Buy and raises the price target from $7.5 to $10.
Read original at benzinga
NERV
BenzingaAug 7, 2026, 11:42 AMBenzinga Newsdesk
Minerva Neurosciences Q2 Adj. EPS $(0.10) Beats $(0.12) Estimate
Minerva Neurosciences (NASDAQ:NERV) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.12) by 9.09 percent. This is a 76.74 percent increase over losses of $(0.43) per share
Read original at benzinga
NERV